Response to influenza virus vaccination during chemotherapy in patients with breast cancer

被引:47
作者
Meerveld-Eggink, A. [1 ]
de Weerdt, O. [1 ]
van der Velden, A. M. T. [2 ]
Los, M. [1 ]
van der Velden, A. W. G. [3 ]
Stouthard, J. M. L. [4 ]
Nijziel, M. R. [5 ]
Westerman, M. [6 ]
Beeker, A. [7 ]
van Beek, R. [8 ]
Rimmelzwaan, G. F. [8 ]
Rijkers, G. T. [9 ]
Biesma, D. H. [1 ,10 ]
机构
[1] St Antonius Hosp Nieuwegein, Dept Internal Med, NL-3430 BE Nieuwegein, Netherlands
[2] Tergooi Hosp Blaricum, Dept Internal Med, Blaricum, Netherlands
[3] Martini Hosp Groningen, Dept Internal Med, Groningen, Netherlands
[4] Maasstad Hosp Rotterdam, Dept Internal Med, Rotterdam, Netherlands
[5] Maxima Med Ctr Eindhoven, Dept Internal Med, Eindhoven, Netherlands
[6] Med Ctr Alkmaar, Dept Internal Med, Alkmaar, Netherlands
[7] Spaarne Hosp Hoofddorp, Dept Internal Med, Hoofddorp, Netherlands
[8] Erasmus MC, Dept Virol, Rotterdam, Netherlands
[9] St Antonius Hosp Nieuwegein, Dept Med Microbiol & Immunol, Nieuwegein, Netherlands
[10] Univ Med Ctr Utrecht, Dept Internal Med, Utrecht, Netherlands
关键词
chemotherapy; haemagglutination inhibition; influenza virus vaccination; ANTIBODY-RESPONSE; IMMUNE-RESPONSE; H1N1; VIRUS; IMMUNIZATION; RECOMMENDATIONS; IMMUNOGENICITY; REACTOGENICITY; EXPERIENCE; VACCINES; CHILDREN;
D O I
10.1093/annonc/mdq728
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Patients receiving chemotherapy are at increased risk for influenza virus infection. Little is known about the preferred moment of vaccination during chemotherapy. Patients and methods: Breast cancer patients received influenza vaccination during FEC (5-fluorouracil, epirubicin and cyclophosphamide)-containing chemotherapy regimens. Patients were randomised for early (day 4) or late (day 16) vaccination during the chemotherapy cycle. Influenza virus-specific antibody titres were determined before and 3 weeks after vaccination by haemagglutination inhibition. Results: We included 38 breast cancer patients (20 in the early and 18 in the late group) and 21 healthy controls. The overall patient group had significant lower responses to the vaccine compared with healthy controls. Patients vaccinated at day 4 tended to have higher antibody titres as compared with patients vaccinated at day 16, although the difference in post-vaccination titres is not statistically significant. Geometric mean titres post-vaccination for day 4 versus day 16 were 63.7 versus 29.5 (H3N2), 28.2 versus 19.6 (H1N1) and 29.8 versus 16.0 (B/Brisbane), respectively. Conclusions: Patients on chemotherapy have significantly lower responses to influenza virus vaccination compared with healthy controls. Vaccination early during the chemotherapy cycle induces better responses than does vaccination at day 16 of the cycle. Follow-up studies are needed to confirm this effect.
引用
收藏
页码:2031 / 2035
页数:5
相关论文
共 21 条
[1]  
Arrowood JR, 2002, ANN PHARMACOTHER, V36, P1219
[2]   Humoral immune response after vaccination against influenza in patients with breast cancer [J].
Brydak, LB ;
Guzy, J ;
Starzyk, J ;
Machala, M ;
Gózdz, SS .
SUPPORTIVE CARE IN CANCER, 2001, 9 (01) :65-68
[3]  
Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P521
[4]  
Committee for Proprietary Medicinal Products (CPMP), 1997, CPMPBWP21496
[5]   Epidemiology and outcomes of serious influenza-related infections in the cancer population [J].
Cooksley, CD ;
Avritscher, EBC ;
Bekele, BN ;
Rolston, KV ;
Geraci, JM ;
Elting, LS .
CANCER, 2005, 104 (03) :618-628
[6]   HARMONIZATION OF REQUIREMENTS FOR INFLUENZA-VIRUS VACCINES - THE FIRST YEARS EXPERIENCE WITH THE EEC GUIDELINE [J].
DAMEN, JEGPC .
BIOLOGICALS, 1993, 21 (02) :179-182
[7]   REACTOGENICITY AND IMMUNOGENICITY OF A SURFACE-ANTIGEN-ADSORBED INFLUENZA-VIRUS VACCINE IN CHILDREN [J].
EASTWOOD, LM ;
JENNINGS, R ;
MILNER, RDG ;
POTTER, CW .
JOURNAL OF CLINICAL PATHOLOGY, 1979, 32 (06) :534-537
[8]  
Fiore Anthony E., 2008, Morbidity and Mortality Weekly Report, V57, P1
[9]   Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible [J].
Gelinck, L. B. S. ;
van den Bemt, B. J. F. ;
Marijt, W. A. F. ;
van der Bijl, A. E. ;
Visser, L. G. ;
Cats, H. A. ;
Rimmelzwaan, G. F. ;
Kroon, F. P. .
VACCINE, 2009, 27 (18) :2469-2474
[10]  
GROSS PA, 1985, REV INFECT DIS, V7, P613